158 related articles for article (PubMed ID: 22809434)
21. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.
Patel KP; Barkoh BA; Chen Z; Ma D; Reddy N; Medeiros LJ; Luthra R
J Mol Diagn; 2011 Nov; 13(6):678-86. PubMed ID: 21889610
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
[TBL] [Abstract][Full Text] [Related]
24. Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.
Hao Z; Cairns RA; Inoue S; Li WY; Sheng Y; Lemonnier F; Wakeham A; Snow BE; Dominguez-Brauer C; Ye J; Larsen DM; Straley KS; Tobin ER; Narayanaswamy R; Gaulard P; Mak TW
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1387-92. PubMed ID: 26787889
[TBL] [Abstract][Full Text] [Related]
25. Pediatric Acute Lymphoblastic Leukemia With Hypereosinophilia and IDH2 Gene Mutation: A Case Report and Literature Review.
Gho DS; Cooper RM
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e546-e549. PubMed ID: 34966098
[TBL] [Abstract][Full Text] [Related]
26. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Kato Kaneko M; Liu X; Oki H; Ogasawara S; Nakamura T; Saidoh N; Tsujimoto Y; Matsuyama Y; Uruno A; Sugawara M; Tsuchiya T; Yamakawa M; Yamamoto M; Takagi M; Kato Y
Cancer Sci; 2014 Jun; 105(6):744-8. PubMed ID: 24898068
[TBL] [Abstract][Full Text] [Related]
27. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of
Ferret Y; Boissel N; Helevaut N; Madic J; Nibourel O; Marceau-Renaut A; Bucci M; Geffroy S; Celli-Lebras K; Castaigne S; Thomas X; Terré C; Dombret H; Preudhomme C; Renneville A
Haematologica; 2018 May; 103(5):822-829. PubMed ID: 29472349
[TBL] [Abstract][Full Text] [Related]
29. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
30. [Detection of isocitrate dehydrogenase 1 gene mutation in 205 AML patients and its clinical significance].
Shang Z; Wang D; Xiao M; Geng Z; Wang HX; Wang J; Xu YL; Li TJ; Zhou JF; Li CR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1307-11. PubMed ID: 23257422
[TBL] [Abstract][Full Text] [Related]
31. Effects of azacitidine in 93 patients with
Willekens C; Rahme R; Duchmann M; Vidal V; Saada V; Broutin S; Delahousse J; Renneville A; Marceau A; Clappier E; Uzunov M; Rossignol J; Pascal L; Simon L; Micol JB; Pasquier F; Raffoux E; Preudhomme C; Quivoron C; Itzykson R; Penard-Lacronique V; Paci A; Fenaux P; Attar EC; Frattini M; Braun T; Ades L; De Botton S
Leuk Lymphoma; 2021 Feb; 62(2):438-445. PubMed ID: 33043739
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.
Green CL; Evans CM; Hills RK; Burnett AK; Linch DC; Gale RE
Blood; 2010 Oct; 116(15):2779-82. PubMed ID: 20651067
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
[TBL] [Abstract][Full Text] [Related]
34. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Platt MY; Fathi AT; Borger DR; Brunner AM; Hasserjian RP; Balaj L; Lum A; Yip S; Dias-Santagata D; Zheng Z; Le LP; Graubert TA; Iafrate AJ; Nardi V
J Mol Diagn; 2015 Nov; 17(6):661-8. PubMed ID: 26331834
[TBL] [Abstract][Full Text] [Related]
35. Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
Hartman DJ; Binion D; Regueiro M; Schraut W; Bahary N; Sun W; Nikiforova M; Pai RK
Am J Surg Pathol; 2014 Aug; 38(8):1147-56. PubMed ID: 25029120
[TBL] [Abstract][Full Text] [Related]
36. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
Chou WC; Hou HA; Chen CY; Tang JL; Yao M; Tsay W; Ko BS; Wu SJ; Huang SY; Hsu SC; Chen YC; Huang YN; Chang YC; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2010 Apr; 115(14):2749-54. PubMed ID: 20097881
[TBL] [Abstract][Full Text] [Related]
37. NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation.
Raman HS; Shanmugam V; Li J; Steensma DP; Kim AS; Luskin MR
Leuk Lymphoma; 2021 Jul; 62(7):1790-1792. PubMed ID: 33586600
[No Abstract] [Full Text] [Related]
38. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
[TBL] [Abstract][Full Text] [Related]
39. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
